Title:Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Volume: 9
Issue: 2
Author(s): Georgios V. Koukourakis
Affiliation:
Keywords:
Avastin, bevacizumab, chemotherapy, glioblastoma multiforme, malignant brain gliomas, radiation therapy, treatment.
Abstract: Recently, the improvement of innovative medications named focused treatments represents
the consequence of a superior knowledge of the procedures implicated in the modification of physiological
tissues in tumor. Focused treatment is known as the therapy which uses specific substances
that affect selective mechanisms implicated in tumorigenesis and tumor development. Angiogenesis is
important for tumor development and distant metastatic disease and represents a significant aim for
modern biological substances. Bevacizumab belongs to humanized recombinant antibody family which obviates vascular
endothelial growth factor (VEGF) receptor fastening, and suspending genesis of new vessels and tumor development.
Bevacizumab represents the primary antiangiogenic treatment authorized for usage in tumor and has FDA authorization to
treat the recurrent glioblastoma multiform since 2009. Bevacizumab’s efficiency for treating malignant brain gliomas
along with correlated patent appliances related to this agent is discussed below.
